Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus CAV or Topotecan as Treatment in Patients With Small-Cell Lung Cancer
- Conditions
- Small-cell Lung Cancer
- Interventions
- Registration Number
- NCT02566993
- Lead Sponsor
- PharmaMar
- Brief Summary
Phase III randomized clinical trial of lurbinectedin (PM01183)/doxorubicin (DOX) versus cyclophosphamide (CTX), doxorubicin (DOX) and vincristine (VCR) (CAV) or topotecan as treatment in patients with small-cell lung cancer (SCLC) who failed one prior platinum-containing line.
- Detailed Description
Multicenter, open-label, randomized, controlled phase III clinical trial to evaluate and compare the activity and safety of an experimental arm consisting of PM01183/DOX combination followed by PM01183 alone, if applicable vs. best Investigator's choice between CAV or topotecan as a control arm, in SCLC patients who failed one prior platinum-containing line but no more than one prior chemotherapy-containing line.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 613
- Voluntary written informed consent
- Adult patients ≥ 18 years
- Histologically or cytologically confirmed diagnosis of limited or extensive stage SCLC which failed one prior platinum-containing regimen and with a chemotherapy-free interval (CTFI, time from the last dose of first-line chemotherapy to the occurrence of progressive disease) ≥ 30 days. Small-cell carcinoma of unknown primary site with or without neuroendocrine features confirmed in histology test(s) performed on metastatic lesion(s) are eligible, if Ki-67/MIB-1 is expressed in >50% of tumor cells.
- Eastern Cooperative Oncology Group Performance Status (ECOG PS) ≤ 2.
- Adequate hematological, renal, metabolic and hepatic function within 7-10 days prior to randomization
- At least three weeks since last prior anticancer treatment and adequate recovery from prior treatment toxicity
- Prior radiotherapy (RT): At least four weeks since completion of whole-brain irradiation, at least two weeks since completion of prophylactic cranial irradiation, and to any other site.
- Evidence of non-childbearing status for women of childbearing potential (WOCBP). WOCBP must agree to use a highly effective contraceptive measure up to six weeks after treatment discontinuation. Fertile male patients with WOCBP partners should use condoms during treatment and for four months following the last investigational medicinal product dose.
-
More than one prior chemotherapy-containing line(re-challenge with the same initial regimen is not allowed)
-
Patients who never received platinum-containing regimen for Small-cell Lung Cancer (SCLC)
-
Prior treatment with PM01183, topotecan or anthracyclines.
-
Limited-stage patients who are candidates for local or regional therapy
-
Impending need for palliative RT or surgery for pathological fractures and/or for medullary compression within four weeks prior to randomization.
-
Symptomatic or progressing or steroid requiring Central Nervous System (CNS) involvement disease at least four weeks prior to randomization
-
Concomitant diseases/conditions:
Angina, myocardial infarction, congestive heart failure or clinically significant valvular heart disease, arrhythmia, immunodeficiency (including known HIV seropositive), ongoing or treatment-requiring chronic liver disease, active infection, oxygen requirement within two weeks prior to randomization, diffuse interstitial lung disease (ILD) or pulmonary fibrosis, second invasive malignancy treated with chemotherapy and/or radiotherapy, invasive fungal infections requiring systemic treatment within 12 weeks of randomization.
-
Pregnant or breast feeding women
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Control Arm 1 Doxorubicin (DOX) CAV (Cyclophosphamide (CTX), Doxorubicin (DOX) and Vincristine (VCR)) Experimental Arm Lurbinectedin (PM01183) Lurbinectedin (PM01183) / Doxorubicin Control Arm 1 Cyclophosphamide (CTX) CAV (Cyclophosphamide (CTX), Doxorubicin (DOX) and Vincristine (VCR)) Experimental Arm Doxorubicin (DOX) Lurbinectedin (PM01183) / Doxorubicin Control Arm 1 Vincristine (VCR) CAV (Cyclophosphamide (CTX), Doxorubicin (DOX) and Vincristine (VCR)) Control Arm 2 Topotecan Topotecan
- Primary Outcome Measures
Name Time Method Overall Survival (OS) Every three months up to death or study termination, a period of approximately 3.5 years Overall survival (OS) will be calculated from the date of randomization to the date of death (death event) or last contact(in this case, survival will be censored on that date).
- Secondary Outcome Measures
Name Time Method Overall Response Rate in Patients Without Central Nervous System Involvement at Baseline Every three months up to death or study termination, a period of approximately 3.5 years Overall response rate is defined as the proportion of patients who have a partial or complete response in the best antitumor response. The best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1.
CR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknownBest Antitumor Response in Patients With Chemotherapy-free Interval <90 Days Every three months up to death or study termination, a period of approximately 3.5 years Best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1.
CR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknownDifference in Overall Survival Between Lurbinectedin/Doxorubicin (DOX) and CAV in Patients With CAV as Best Investigator's Choice: Overall Survival Rate at 12 Months At 12 months Overall survival (OS) will be calculated from the date of randomization to the date of death (death event) or last contact(in this case, survival will be censored on that date).
Progression-free Survival (PFS) by Independent Review Committee Every six weeks up to progression disease, a period of approximately 3.5 years Progression-free survival (PFS) is defined as the time from the date of randomization to the date of documented progression per RECIST v.1.1 or death (regardless of the cause of death). If the patient receives further antitumor therapy or is lost to follow-up before PD, PFS will be censored at the date of last tumor assessment before the date of subsequent antitumor therapy.
Progression-free Survival Rate at 6 Months by Independent Review Committee At 6 months Progression-free survival (PFS) is defined as the time from the date of randomization to the date of documented progression per RECIST v.1.1 or death (regardless of the cause of death). If the patient receives further antitumor therapy or is lost to follow-up before PD, PFS will be censored at the date of last tumor assessment before the date of subsequent antitumor therapy.
Progression-free Survival Rate at 12 Months by Independent Review Committee at 12 months Progression-free survival (PFS) is defined as the time from the date of randomization to the date of documented progression per RECIST v.1.1 or death (regardless of the cause of death). If the patient receives further antitumor therapy or is lost to follow-up before PD, PFS will be censored at the date of last tumor assessment before the date of subsequent antitumor therapy.
Best Antitumor Response by Independent Review Committee Every three months up to death or study termination, a period of approximately 3.5 years Best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1.
CR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknownDuration of Response by Independent Review Committee Every three months up to death or study termination, a period of approximately 3.5 years Duration of Response is defined as the time that patients who have a partial or complete response in the best antitumor response. The best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1.
CR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknownOverall Response Rate in Patients With Chemotherapy-free Interval ≥ 90 Days Every three months up to death or study termination, a period of approximately 3.5 years Overall response rate is defined as the proportion of patients who have a partial or complete response in the best antitumor response. The best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1.
CR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknownProgression-free Survival in Patients With Chemotherapy-free Interval <90 Days Every six weeks up to progression disease, a period of approximately 3.5 years Progression-free survival (PFS) is defined as the time from the date of randomization to the date of documented progression per RECIST v.1.1 or death (regardless of the cause of death). If the patient receives further antitumor therapy or is lost to follow-up before PD, PFS will be censored at the date of last tumor assessment before the date of subsequent antitumor therapy.
Difference in Overall Survival Between Lurbinectedin/DOX and CAV in Patients With CAV as Best Investigator's Choice: Overall Survival Rate at 18 Months At 18 months Overall survival (OS) will be calculated from the date of randomization to the date of death (death event) or last contact(in this case, survival will be censored on that date).
Difference in Overall Survival Between Lurbinectedin/DOX and CAV in Patients With CAV as Best Investigator's Choice: Overall Survival Rate at 24 Months At 24 months Overall survival (OS) will be calculated from the date of randomization to the date of death (death event) or last contact(in this case, survival will be censored on that date).
Overall Response Rate by Independent Review Committee Every three months up to death or study termination, a period of approximately 3.5 years Overall response rate is defined as the proportion of patients who have a partial or complete response in the best antitumor response. The best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1.
CR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknownOverall Survival in Patients With Chemotherapy-free Interval ≥ 90 Days Every three months up to death or study termination, a period of approximately 3.5 years Overall survival (OS) will be calculated from the date of randomization to the date of death (death event) or last contact(in this case, survival will be censored on that date).
Duration of Response in Patients With Chemotherapy-free Interval ≥ 90 Days Every three months up to death or study termination, a period of approximately 3.5 years Duration of Response is defined as the time that patients who have a partial or complete response in the best antitumor response. The best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1.
CR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknownOverall Survival in Patients Without Central Nervous System Involvement at Baseline Every three months up to death or study termination, a period of approximately 3.5 years Overall survival (OS) will be calculated from the date of randomization to the date of death (death event) or last contact(in this case, survival will be censored on that date).
Overall Survival in Patients With Central Nervous System Involvement at Baseline Every three months up to death or study termination, a period of approximately 3.5 years Overall survival (OS) will be calculated from the date of randomization to the date of death (death event) or last contact(in this case, survival will be censored on that date).
Best Antitumor Response in Patients With Central Nervous System Involvement at Baseline Every three months up to death or study termination, a period of approximately 3.5 years Best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1.
CR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknownOverall Response Rate in Patients With Chemotherapy-free Interval <90 Days Every three months up to death or study termination, a period of approximately 3.5 years Overall response rate is defined as the proportion of patients who have a partial or complete response in the best antitumor response. The best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1.
CR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknownProgression-free Survival in Patients With Chemotherapy-free Interval ≥90 Days Every six weeks up to progression disease, a period of approximately 3.5 years Progression-free survival (PFS) is defined as the time from the date of randomization to the date of documented progression per RECIST v.1.1 or death (regardless of the cause of death). If the patient receives further antitumor therapy or is lost to follow-up before PD, PFS will be censored at the date of last tumor assessment before the date of subsequent antitumor therapy.
Best Antitumor Response in Patients With Chemotherapy-free Interval ≥ 90 Days Every three months up to death or study termination, a period of approximately 3.5 years Best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1.
CR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknownOverall Survival in Patients With Chemotherapy-free Interval < 90 Days Every three months up to death or study termination, a period of approximately 3.5 years Overall survival (OS) will be calculated from the date of randomization to the date of death (death event) or last contact(in this case, survival will be censored on that date).
Progression-free Survival in Patients Without Central Nervous System Involvement at Baseline Every six weeks up to progression disease, a period of approximately 3.5 years Progression-free survival (PFS) is defined as the time from the date of randomization to the date of documented progression per RECIST v.1.1 or death (regardless of the cause of death). If the patient receives further antitumor therapy or is lost to follow-up before PD, PFS will be censored at the date of last tumor assessment before the date of subsequent antitumor therapy.
Best Antitumor Response in Patients Without Central Nervous System Involvement at Baseline Every three months up to death or study termination, a period of approximately 3.5 years Best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1.
CR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknownDuration of Response in Patients With Chemotherapy-free Interval <90 Days Every three months up to death or study termination, a period of approximately 3.5 years Duration of Response is defined as the time that patients who have a partial or complete response in the best antitumor response. The best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1.
CR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknownDuration of Response in Patients With Central Nervous System Involvement at Baseline Every three months up to death or study termination, a period of approximately 3.5 years Duration of Response is defined as the time that patients who have a partial or complete response in the best antitumor response. The best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1.
CR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknownDuration of Response in Patients Without Central Nervous System Involvement at Baseline Every three months up to death or study termination, a period of approximately 3.5 years Duration of Response is defined as the time that patients who have a partial or complete response in the best antitumor response. The best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1.
CR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknownProgression-free Survival in Patients With Central Nervous System Involvement at Baseline Every six weeks up to progression disease, a period of approximately 3.5 years Progression-free survival (PFS) is defined as the time from the date of randomization to the date of documented progression per RECIST v.1.1 or death (regardless of the cause of death). If the patient receives further antitumor therapy or is lost to follow-up before PD, PFS will be censored at the date of last tumor assessment before the date of subsequent antitumor therapy.
Overall Response Rate in Patients With Central Nervous System Involvement at Baseline Every three months up to death or study termination, a period of approximately 3.5 years Overall response rate is defined as the proportion of patients who have a partial or complete response in the best antitumor response. The best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1.
CR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknown
Trial Locations
- Locations (160)
Center for Pneumology and Thoracic Surgery
🇩🇪Gerlingen, Germany
University Multiprofile Hospital for Active Treatment "Sv. Ivan Rilski", Sofia
🇧🇬Sofia, Bulgaria
Vivantes Klinikum am Urban, Hämatologie und Onkologie
🇩🇪Berlin, Germany
Centre François Baclesse
🇫🇷Caen, France
Centre Hospitalier Intercommunal de Créteil
🇫🇷Creteil, France
Evangelische Lungenklinik Berlin
🇩🇪Berlin, Germany
CHU de Rennes Hôpital Pontchaillou
🇫🇷Rennes, France
Multiprofile Hospital for Active Treatment of Women Health - "Nadezhda", Sofia; Clinic of Medical Oncology
🇧🇬Sofia, Bulgaria
Acibadem City Clinic University Multiprofile Hospital for Active Treatment. EOOD, Sofia; Clinic of Medical Oncology
🇧🇬Sofia, Bulgaria
Vitkovicka nemocnice, a.s., Plicni oddeleni
🇨🇿Ostrava, Czechia
lnstituto de Ensino e Pesquisa Säo Lucas - IEP Säo Lucas
🇧🇷Sao Paulo, São Paulo, Brazil
Hospital São Lucas da PUCRS
🇧🇷Porto Alegre, RS, Brazil
Centre Antoine Lacassagne
🇫🇷Nice Cedex 2, France
University of Munich LMU, Dpt. of Medicine V
🇩🇪Munchen, Germany
Asklepios-Fachkliniken München Gauting
🇩🇪Gauting, Germany
Hospital de clínicas de Porto alegre
🇧🇷Pôrto Alegre, RS, Brazil
Biron (Clinique René Laennec)
🇨🇦Mont-Royal, Quebec, Canada
Multiprofile Hospital for Active Treatment - Uni Hospital, Panagyurishte
🇧🇬Panagyurishte, Bulgaria
lRCCS-Arcispedale Santa Maria Nuova
🇮🇹Reggio Emilia, Italy
Fundação PlO XII - Hospital de Câncer de Barretos
🇧🇷Barretos, São Paulo, Brazil
Katholisches Klinikum Koblenz-Montabaur, Marienhof Koblenz
🇩🇪Koblenz, Germany
Städtisches Krankenhaus München Neuperlach
🇩🇪Munchen, Germany
General Hospital of Thessaloniki "G. Papanikolaou", Pulmonary Clinic, Aristotle University of Thessaloniki
🇬🇷Thessaloniki, Greece
Centre intégré de santé et de services sociaux de la Montérégie Centre
🇨🇦Greenfield Park, Quebec, Canada
Centre Hospitalier Lyon Sud - Service de Pneumologie
🇫🇷Lyon, France
Centro di Riferimento Oncologico di Aviano
🇮🇹Aviano, Italy
Associação Hospital de Caridade de Ijuí
🇧🇷Ijui, RS, Brazil
VIDIA Christliche Kliniken Karlsruhe
🇩🇪Karlsruhe, Germany
Hôpital Nord - Service Oncologie Multidisciplinaire et Innovations Thérapeutiques
🇫🇷Marseille, France
Klinik Löwenstein gGmbH, Med. Klinik II Onkologie
🇩🇪Löwenstein, Germany
Thoraxklinik Heidelberg GmbH
🇩🇪Heidelberg, Germany
Krajska zdravotni a.s. Masarykova nemocnice o.z.
🇨🇿Usti nad Labem, Czechia
lrmandade da Santa Casa de Misericórdia de Porto Alegre
🇧🇷Porto Alegre, RS, Brazil
Lungenklinik Hemer
🇩🇪Hemer, Germany
AOU Maggiore della Carità - SC Oncologia
🇮🇹Novara, Italy
Istituto Oncologico Veneto
🇮🇹Padova, Italy
Institut Bergonié
🇫🇷Bordeaux, France
Onkologische Schwerpunktpraxis Leer-Emden
🇩🇪Leer, Germany
Uniklinik Freiburg, Hämatologie, Onkologie & Stammzellransplantation
🇩🇪Freiburg, Germany
Johannes Wesling Klinikum Minden, Klinik für Hämatologie, Onkologie und Palliativmedizin
🇩🇪Minden, Germany
Central Clinic of Bad Berka
🇩🇪Bad Berka, Germany
The Christie NHS Fundation Trust
🇬🇧Manchester, Greater Manchester, United Kingdom
Sarah Cannon Research Institute UK
🇬🇧London, United Kingdom
Miskolci Semmelweis Kórház és Egyetemi Oktatókórház, Pulmonológiai Osztály
🇭🇺Miskolc, Hungary
Ain Wazein Hospital
🇱🇧Ain Wazein, El Chouf, Lebanon
Hospital Universitario Puerta de Hierro Majadahonda
🇪🇸Majadahonda, Madrid, Spain
Complejo hospitalario regional virgen rocío
🇪🇸Sevilla, Spain
ASST Grande Ospedale Metropolitano Niguarda
🇮🇹Milano, MI, Italy
Szpitale Pomorskie Sp. z o.o., Oddzial Onkologii Klinicznej, Oddzial Onkologii i Radioterapii
🇵🇱Gdynia, Poland
Centro Hospitalar do Porto, EPE - Hospital de Santo António
🇵🇹Porto, Portugal
SC Oncolab SRL
🇷🇴Craiova, Judet Dolj, Romania
Hospital Universitario Reina Sofia
🇪🇸Cordoba, Spain
Hospital Universitario Clínico San Carlos
🇪🇸Madrid, Spain
Policlinico Universitario Campus Bio-Medico
🇮🇹Roma, Italy
American University of Beirut Medical Center
🇱🇧Beirut, Lebanon
Bristol Cancer Institute, UHB NHS Foundation Trust
🇬🇧Bristol, United Kingdom
Hospital Universitari Vall d' Hebron
🇪🇸Barcelona, Spain
Hospital General Universitario de Valencia
🇪🇸Valencia, Spain
Worcestershire Acute Hospitals NHS Trust
🇬🇧Worcester, United Kingdom
MD Anderson Cancer Center Madrid
🇪🇸Madrid, Spain
Bialostockie Centrum Onkologii im. Marii Sklodowskiej-Curie; Oddzial Onkologii Klinicznej im. dr Ewy Pileckiej z pododdzialem
🇵🇱Białystok, Poland
Centro Clínico Champalimaud - Fundação Champalimaud
🇵🇹Lisboa, Portugal
Hospital Universitario Miguel Servet
🇪🇸Zaragoza, Spain
Hospital Universitario Ramón y Cajal
🇪🇸Madrid, Spain
Spaarne Gasthuis
🇳🇱Hoofddorp, Netherlands
Maxima Medisch Centrum
🇳🇱Veldhoven, Netherlands
Hospital Universitario Fundación Jiménez Díaz
🇪🇸Madrid, Spain
Boca Raton Regional Hospital Lynn Cancer Institute
🇺🇸Boca Raton, Florida, United States
Massachusetts General Hospital
🇺🇸Boston, Massachusetts, United States
Southlake Regional Health Centre - Stronach Regional Cancer Centre
🇨🇦Newmarket, Ontario, Canada
R.S. Mc Laughlin Durham Regional Cancer Centre, Lakeridge Health
🇨🇦Oshawa, Ontario, Canada
Centro Hospitalar de São João, EPE
🇵🇹Porto, Portugal
Montreal Oncology Research Inc.
🇨🇦Montreal, Quebec, Canada
Hotel Dieu de France
🇱🇧Beirut, Lebanon
MUMC
🇳🇱Maastricht, Netherlands
General Hospital of Chest Diseases of Athens "Sotiria"
🇬🇷Athens, Greece
Hammoud Hospital University Medical Center
🇱🇧Sidon, Lebanon
Centro Hospitalar Lisboa Norte, EPE- Hospital Pulido Valente
🇵🇹Lisboa, Portugal
Institutul Oncologic "Prof. Dr. Ion Chiricuta" Cluj-Napoca, Departament Oncologie Medicala
🇷🇴Cluj, Romania
IRCCS CROB (Istituto di Ricovero e Cura a Carattere Scientifico)
🇮🇹Rionero in Vulture, PZ, Italy
Azienda Ospedaliero - Universitaria "Policlinico - Vittorio Emanuele" - Presidio G. Rodolico
🇮🇹Catania, Italy
ASST della Valtellina e dell' Alto Lario P.O. Di Sondrio
🇮🇹Sondrio, Italy
University College London Hospitals NHS Foundation Trust
🇬🇧London, United Kingdom
St Jude Hospital Yorba Linda dba St Joseph Heritage Healthcare
🇺🇸Fullerton, California, United States
Loma Linda University Medica! Center
🇺🇸Loma Linda, California, United States
Innovative Clinical Research Institute (ICRI)
🇺🇸Whittier, California, United States
Joliet Oncology-Hematology Associates, Ltd.
🇺🇸Joliet, Illinois, United States
Healthcare Research Network III, LLC
🇺🇸Tinley Park, Illinois, United States
Carle Cancer Center
🇺🇸Urbana, Illinois, United States
Montgomery Cancer Center
🇺🇸Mount Sterling, Kentucky, United States
East Jefferson Hematology-Oncology Metairie Physicians Services, Inc
🇺🇸Metairie, Louisiana, United States
Anne Arundel Medical Center Oncology and Hematology
🇺🇸Annapolis, Maryland, United States
QUEST Research Institute
🇺🇸Royal Oak, Michigan, United States
Dartmouth-Hitchcock Medical Center/Mary Hitchcock Memorial Hospital
🇺🇸Lebanon, New Hampshire, United States
Summit Medical Group, P.A.
🇺🇸Florham Park, New Jersey, United States
FirstHealth Outpatient Cancer Center
🇺🇸Pinehurst, North Carolina, United States
Gabrail Cancer Center Research
🇺🇸Canton, Ohio, United States
Oklahoma Cancer Specialists and Research Institute, LLC
🇺🇸Tulsa, Oklahoma, United States
Associates in Hematology and Oncology, P.C.
🇺🇸Upland, Pennsylvania, United States
Tyler Hematology-Oncology PA
🇺🇸Tyler, Texas, United States
The Center for Cancer and Blood Disorders
🇺🇸Fort Worth, Texas, United States
Medical Oncology Associates PS (dba Summit Cancer Centers)
🇺🇸Spokane, Washington, United States
MultiCare Institute for Research & Innovation
🇺🇸Tacoma, Washington, United States
Instituto Médico Especializado Alexander Fleming
🇦🇷C.a.b.a., Buenos Aires, Argentina
CORI - Centro Oncológico Riojano Integral
🇦🇷La Rioja, Argentina
ISIS Centro Especializado de Luce S.A.
🇦🇷Santa Fe, Argentina
Universitätsklinik für Innere Medizin III der PMU
🇦🇹Salzburg, Austria
Medizinische Universität Wien / AKH Wien, Universitätsklinik für Innere Medizin I, Abteilung für klinische Onkologie
🇦🇹Wien, Austria
AZ Maria Middelares
🇧🇪Gent, Belgium
Clinique André Renard
🇧🇪Herstal, Belgium
CHU de Liege - Sart Tilman
🇧🇪Liege, Belgium
CHR de la citadelle
🇧🇪Liege, Belgium
CHU Ambroise Paré
🇧🇪Mons, Belgium
AZ Delta Campus Wilgenstraat
🇧🇪Roeselare, Belgium
lOP- Instituto de oncologia do paraná
🇧🇷Curitiba, Paraná, Brazil
Coordenação de Pesquisa Clínica / Instituto Nacional de Câncer
🇧🇷Rio de Janeiro, RJ, Brazil
Instituto COl de Pesquisa, Educação e Gestão
🇧🇷Rio de Janeiro, RJ, Brazil
Nucleo de Oncologia da Bahia
🇧🇷Salvador, BA, Brazil
Klinikum Bogenhausen, Städt. Klinikum München GmbH, Klinik für Pneumologie und Pneumologische Onkologie
🇩🇪Munchen, Germany
Uniklinikum Mannheim, TTZ, Medizinische Fakultät Mannheim
🇩🇪Mannheim, Germany
Klinikum Nürnberg Nord - Pneumologische Onkologie
🇩🇪Nuremberg, Germany
Universitätsklinikum Ulm - Klinik für Innere Medizin II, Pneumologie
🇩🇪Ulm, Germany
Medizinische Klinik I
🇩🇪Wuppertal, Germany
Hospital Universitario 12 de Octubre
🇪🇸Madrid, Spain
Hospital Regional Universitario de Malaga
🇪🇸Malaga, Spain
Hospital Universitario La Fe de Valencia
🇪🇸Valencia, Spain
Holy Cross Hospital - Michael and Dianne Bienes Comprehensive Cancer Center
🇺🇸Fort Lauderdale, Florida, United States
Alabama Oncology
🇺🇸Birmingham, Alabama, United States
H. Lee Moffitt Cancer Center & Research Institute
🇺🇸Tampa, Florida, United States
Norton Cancer Institute
🇺🇸Louisville, Kentucky, United States
Comprehensive Cancer Centers of Nevada
🇺🇸Las Vegas, Nevada, United States
Froedtert Hospital & the Medical College of Wisconsin
🇺🇸Milwaukee, Wisconsin, United States
Centre Hospitalier Universitaire Notre Dame de Secours
🇱🇧Biblos, Lebanon
Instituto Oncológico de Córdoba (IONC)
🇦🇷Córdoba, Argentina
General Oncology Hospital of Kifissia "Agioi Anargiroi", 2nd Internal Medicine-Oncology Clinic
🇬🇷Athens, Greece
Fejér Megyei Szent György Egyetemi Oktató Kórház, I. Pulmonológiai Osztály
🇭🇺Szekesfehervar, Hungary
Markusovszky Egyetemi Oktatókórház, Pulmonológiai Osztály
🇭🇺Szombathely, Hungary
Ironwood Physicians P.C. dba Ironwood Cancer & Research Centers
🇺🇸Chandler, Arizona, United States
Országos Korányi TBC és Pulmonológiai lntézet, 14. Pulmonológia
🇭🇺Budapest, Hungary
McGill University Health Centre
🇨🇦Montréal, Quebec, Canada
University General Hospital of Heraklion - General Hospital "Venizeleio"
🇬🇷Heraklion, Crete, Greece
Mátrai Gyógyintézet, Bronchológia
🇭🇺Matrahaza, Hungary
Szent Borbála Kórház, Pulmonológiai osztály
🇭🇺Tatabanya, Hungary
Zala Megyei Kórház, Pulmonologia
🇭🇺Zalaegerszeg, Hungary
Veszprém Megyei Tüdögyógyintézet, 3. Pulmonológiai Osztály
🇭🇺Farkasgyepu, Hungary
The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital
🇳🇱Amsterdam, Netherlands
Szpital Kliniczny Przemienienia Pańskiego Uniwersytetu Medycznego im. K.Marcinkowskiego w Poznaniu, Oddzial Chemioterapii
🇵🇱Poznań, Poland
Hospital CUF Porto
🇵🇹Porto, Portugal
Instituto Português de Oncologia do Porto Francisco Gentil, EPE
🇵🇹Porto, Portugal
SC Centrul de Oncologie Sf. Nectarie SRL, Departament Oncologie Medícala
🇷🇴Craiova, Dolj, Romania
Spitalul Clinic Judetean de Urgenta "Sf. Apostol Andrei"
🇷🇴Constanta, Judet Constanta, Romania
Országos Korányi TBC és Pulmonológiai Intézet, 6. Pulmonológia és Bronchologia
🇭🇺Budapest, Hungary
Corporació Sanitaria Parc Taulí-Hospital de Sabadell
🇪🇸Sabadell, Barcelona, Spain
Mazowieckie Centrum Leczenia Chorób Pluc i Gruźlicy Oddzial III Chorób Pluc z Pododdzialem Onkologicznym
🇵🇱Otwock, Poland
Hospital Universitari Germans Trias i Pujol ICO
🇪🇸Badalona, Barcelona, Spain
Spitalul Judetean de Urgenta "Dr. Constantin Opris", Sectia Oncologie Medicala
🇷🇴Baia Mare, Maramures, Romania
Institutul Oncologic "Prof. Dr. lon Chiricuta" Cluj-Napoca, Dcpartamentul Oncologie Medicala
🇷🇴Cluj, Romania
Institutul Oncologic "Prof. Dr. lon Chiricuta" Cluj-Napoca, Sectia Oncologic Medicala
🇷🇴Cluj, Romania
The Clatterbridge Cancer Centre NHS Foundation Trust
🇬🇧Bebington, Wirral, United Kingdom
Centro para la Atención Integral del Paciente Oncológico (CAIPO)
🇦🇷San Miguel de Tucumán, Tucumán, Argentina
Related News
The Targeted Pulse: Good News for Advanced CLL/SLL With BGB-16673 Receiving Fast ...
- Prev
- 1
- Next